surmount-1 tirzepatide trial obesity without diabetes for Obesity: Highlights from the Early‐Onset Obesity and Tirzepatide Treatment:

The approval of Mounjaro is an exciting step forward for people living with type 2 diabetes given the results seen in these clinical trials. Patrick Archdeacon, MD, associate director of the Division of Diabetes, Lipid Disorders and Obesity within the FDAs Center for Drug Evaluation and Research, also commented on the approval in an agency statement

The trade-off is real, and the regulatory floor sits lower

Tirzepatide injection: Uses, dosing, and safety information

SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeks owenhaskins Oct 16, 2023 3 min read Detailed results from the phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, have revealed Tirzepatide met both co-primary endpoints for the efficacy estimandi and treatment-regimenii estimand, demonstrating superiority to placebo during the 72-week double-blind treatment period

The reduction in the BMI for those receiving tirzepatide and other incretin-based therapies is substantial but is not instantaneous